Investors wiped $70 billion off Novo Nordisk’s market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in the ...

Britain’s regulator approves a dose of up to 7.2 mg of semaglutide per week, up from 2.4 mg.

Novo Nordisk was Europe's most valuable company last year Share price has since lost more than $400 billion Danish economy still outpaces much of the euro zone KALUNDBORG, Denmark, Sept 25 (Reuters) - ...

Dec 23 (Reuters) - Novo Nordisk shares jumped ‌10% on Tuesday after the U.S. Food and ‌Drug Administration approved its weight-loss pill, giving the Danish drugmaker a competitive edge over rival Eli ...

--Down 48.34% year-to-date; on pace for worst year since 1984, when it fell 57.59% --Down 69.75% from its all-time closing high of $146.91 on June 25, 2024 --Down 57.50% from 52 weeks ago (Nov. 25, ...

Novo Nordisk first to market with Wegovy pill Analysts see potential but question if pills are a 'game changer' Advantage for Novo could be short-lived, analysts say The approval of Novo's Wegovy pill ...